

Dry Cow Consult Information Leaflet



Mastitis control program

The Dry Cow consult

The dry period of a dairy cow, between her last day of milking stopping one lactation and her calving beginning the next, is a cornerstone in the effective control of mastitis. Once the udder involutes and is no longer producing milk, the dry period offers the optimum time to use antibiotic dry cow treatment (ADCT) to cure existing subclinical mastitis caused by intramammary infections (IMIs) acquired during the previous lactation. Counterbalancing this, the process of reducing milk production at the end of one lactation and bagging up before the next lactation represents the highest risk period for new IMIs, leading to clinical mastitis early in the following lactation.

There are two main categories for mastitis control treatment over the dry period: ADCT and teat sealants (TS). In conjunction with your trusted veterinary adviser, the information within this booklet is designed to support a more individual cow approach to using these treatments over the dry period. The use of ADCT and TS treatments, combined or individually over the dry period, are significant investments in milk quality for the upcoming lactation. Reviewing their use will maximise the benefits obtained from the responsible use of these products.




Cost of Mastitis

The costs associated with clinical and subclinical mastitis are attributable to: reduced milk production; increased culling or deaths; reduced milk quality and therefore value; veterinary costs; increased labour costs; increasing risk of antibiotic residue violations; and discarded milk. In one study, 64% of the costs attributable to clinical mastitis were due to milk loss, 8% to culling and 28% in treatment costs¹ indicating that the dominant cost is associated with discarded milk (including future production losses). This cost will only increase in higher production cows and as the value of milk rises.

Maximising the benefits of reduced clinical and subclinical mastitis from dry cow treatments will positively impact your farm's profitability. Estimations in Australia place the financial cost of each clinical case of mastitis at approximately \$277². There are also considerable cost savings of reducing your bulk milk cell count (BMCC) and managing subclinical mastitis as described in the table below.

Lowering BMCC Step Diagram*



*Figure 1: Reprinted with permission from:
Fact Sheet R Countdown 2020 Farm Guidelines
for Mastitis Control, Dairy Australia 2014

Working towards greater profitability

Setting targets

Milk quality goals are important to help you achieve results with your mastitis control program. Goals will vary between farms but should focus on areas where a farm may improve to meet the industry benchmarks that have been shown to improve profitability.

	Countdown 2020 Targets	Previous Year's Results	Upcoming Year's Goals
Number of cows	N/A		
Number of clinical mastitis (CM) cases within 14 days after calving	< 5%		
Number of CM cases during lactation each month	< 2%		
BMCC → 250,000 at any point during lactation	No		
Percentage of cows with SCC > 250,000	N/A		
Percentage of new cows (less than 14 days calved) with SCC > 250,000	N/A		
Milk culture results available	Yes		



Quantify the Gains

Using the previous results and the estimated benefit from improving subclinical mastitis and preventing clinical mastitis we can assess any possible economic benefit.

Example Herd

Cow Numbers 200	Previous Year's Results	Upcoming Year's Goals	Benefit	\$ Savings	Target
Bulk Milk Cell Count (average)	250,000	200,000	Dairy Australia estimate of \$56 benefit	200 x \$56 = \$11,200	150,000
Clinical Mastitis within 14 days of calving	8%	6%	2% less cases of mastitis in first 14 days at \$277 per case	0.02 x 200 x \$277 = \$1108	< 5%
Clinical Mastitis rate during lactation per month (9 months)	2.3%	2.1%	0.2% less cases each month at \$277 per case	0.002 x 200 x 9 x \$277 = \$997	< 2%
Potential economic benefit				\$13,305	

Your Herd

Cow Numbers	Previous Year's Results	Upcoming Year's Goals	Benefit	\$ Savings	Target
Bulk Milk Cell Count (average)			Dairy Australia estimate of _____ benefit		
Clinical Mastitis within 14 days of calving			_____ less cases of mastitis in first 14 days at \$277 per case		
Clinical Mastitis rate during lactation per month (9 months)			_____ % less cases each month at \$277 per case		
Potential economic benefit					

Assessing your herd

Cell Count

The somatic cell count is the most important indicator for udder health and is assessed in all herds as the BMCC from a milk vat and in some herds at an individual level (ICCC – Individual Cow Cell Count). Individually, normal milk usually contains between 20,000 to 150,000 cells/mL³ and an IMI, either clinical or subclinical, is the major cause for the ICCC to be elevated above these levels. The BMCC level is the average of the herd's ICCC and is an indication for the broad level of mastitis control for the herd over a long period. It is estimated that for every 100,000 on a BMCC, 10% of the cows are subclinically infected and have elevated ICCC.

An ICCC provides valuable information when drying cows off about the prevalence of infection in individual cows allowing them to be defined as subclinically infected and identifying individual cows with chronic infections that may have poor cure rates with ADCT. The Australian threshold to define a cow as having an IMI and carrying a subclinical infection is 250,000 cells/ml. An individual cow's ICCC is variable and it is suggested to always use multiple ICCC results to define animals as free from subclinical infection or infected.



Type of bacteria causing mastitis

There are two broad groups of bacteria which cause mastitis: contagious and environmental. Differentiation between and within these groups can occur with the use of milk culturing of clinical and subclinical mastitis, and based on ICCC. The areas to focus on for your mastitis control program will vary between these broad groups.

Environmental


Strep uberis is the most common cause of environmental mastitis, with E.coli also occurring frequently. New infections occur mainly in the dry period and are opportunistic, taking advantage of an open teat due to the absence of teat or keratin plug together with circumstances that favour environmental contamination of the teat. New IMIs predominantly occur at the beginning and end of the dry period leading to clinical mastitis early in the following lactation. Teat sealants may be used over the dry period to minimise the number of open teats at risk of a new IMI.

Contagious

Staph aureus is the most common cause of contagious mastitis. New infections occur during lactation when the bacteria is transferred in milk from an infected cow, either clinically or sub clinically, to an uninfected cow. IMIs caused by Staph aureus account for a significant proportion of sub clinically infected cows, making the dry period the optimum time to cure these infections and manage this bacteria.

References

1. Bar et al. The cost of generic clinical mastitis in dairy cows as estimated by using dynamic programming. J Dairy Sci. 2008 Jun;91(6):2205-14
2. Dairy Australia Reference on file.
3. Lee et al 1980. Identification properties, and differential counts of cell populations using electron microscopy of dry cows' secretions, colostrum and milk from normal cows. J. Dairy Res. 47:39.
4. Fact Sheet R Countdown 2020 Farm Guidelines for Mastitis Control, Dairy Australia 2014



GROW WELL

Grow Well

Grow Well aims to develop tools for veterinarians and their clients which may be used in practical situations.

Your veterinarian is the trusted professional with local knowledge to best meet your farm's needs.

Using a greater understanding of your farm's mastitis together with practical considerations, your veterinarian can tailor your dry cow treatment to fit your situation, aiding you with setting and meeting the goals that will ensure your mastitis control.

Produced by

Norbrook Laboratories Australia Pty Ltd

7/1 Trade Park Drive, Tullamarine
Victoria 3043 Australia

Norbrook NZ Ltd

KPMG Centre, 18 Viaduct Harbour Avenue
Auckland, New Zealand

